Green Bamboo Bio has always been focusing on the research and development of biotechnology innovative drugs and infectious disease detection reagents. The company adheres to the tenet of “people-oriented, excellence”, with human vaccines and therapeutic monoclonal antibodies as the main research direction, adheres to independent research and development, and actively introduces international leading technologies to develop and produce market-needed products for disease prevention and control, A variety of vaccine products and biotechnology drugs for disease treatment. The C round of financing was recently completed. Investors include Huapu Haihe Biomedical Fund, Yizhuang Biomedical Fund, CNCB Zhenhua and other institutions. Kaicheng Capital served as financial advisor for three consecutive rounds.
This article is reproduced from: https://www.itjuzi.com/investevent/13306980
This site is for inclusion only, and the copyright belongs to the original author.